Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | GBA1 | P04062 | 2/20 | 0.50 |
| ▸ | NCF1 | P14598 | 2/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.45 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.44 |
| ▸ | VEGFA | P15692 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.44 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.44 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
| ▸ | DTYMK | P23919 | 1/20 | 0.43 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12704686 | 0.86 | CA12 (0.44) | CHRM2CHRM4CHRM1CHRM3ADAM17 | |
| SCHEMBL17826997 | 0.86 | CHRM2 (0.50) | CHRM2CHRM4CHRM1CHRM3GBA1 | |
| SCHEMBL17434260 | 0.84 | NCF1 (0.52) | NCF1 | |
| SCHEMBL24696026 | 0.83 | CHRM2 (0.47) | CHRM2CHRM4CHRM1CHRM3GBA1 | |
| SCHEMBL16855926 | 0.82 | FAAH (0.60) | CHRM2CHRM4CHRM1CHRM3VEGFA | |
| SCHEMBL3709871 | 0.81 | FAAH (0.60) | CHRM2CHRM4CHRM1CHRM3GBA1 | |
| SCHEMBL30422174 | 0.79 | ACHE (0.60) | CHRM2CHRM4CHRM1CHRM3VEGFA | |
| SCHEMBL23293544 | 0.79 | ACHE (0.60) | CHRM2CHRM4CHRM1CHRM3VEGFA | |
| SCHEMBL16830462 | 0.79 | ACHE (0.60) | CHRM2CHRM4CHRM1CHRM3VEGFA | |
| SCHEMBL30958238 | 0.79 | CHRM2 (0.52) | CHRM2CHRM4CHRM1CHRM3GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3088397-A1 | COMPOUNDS THAT ABROGATE THE CELL CYCLE G2 CHECKPOINT FOR USE IN THE TREATMENT OF CANCER | Canbas Co. Ltd. (JP) | 2016-11-02 | — | — | EP | disclosed |
| US-9464076-B2 | Benzothiophene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-10-11 | — | — | US | disclosed |
| US-9464076-B2 | Benzothiophene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-10-11 | — | — | US | disclosed |
| US-9464076-B2 | Benzothiophene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-10-11 | — | — | US | disclosed |
| US-20160024060-A1 | BENZOTHIOPHENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20160024060-A1 | BENZOTHIOPHENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20160024060-A1 | BENZOTHIOPHENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
| EP-2975037-A1 | BENZOTHIOPHENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024060-A1 | BENZOTHIOPHENE DERIVATIVE | PDE10A, PDE5A, PDE3B | CHRM2 3981/4885CHRM4 4212/4885CHRM1 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.